Doctors Should Tell Patients About Some, But Not All, Unexpected Genetic Findings
By Susan Young,
MIT Technology Review
| 03. 22. 2013
On Thursday,
the American College of Medical Genetics and Genomics recommended that doctors tell patients about certain genetic disease risks if they accidentally find them when exploring a patient’s genome for another reason. However, the group does not recommend that doctors tell patients about all incidental findings.
The issue concerns many medical geneticists and other clinicians who use genome data in their practice. When a patient gets genetic testing to hunt for an explanation for heart trouble, should a doctor tell that patient if he or she sees a predisposition for breast cancer or early onset Alzheimer’s disease?
It depends on the disease. The authors of the recommendation write that nearly 60 genetic variants, corresponding to more than 20 conditions, should be examined in all clinical sequencing tests. The authors say the recommended conditions are all likely to be verified by other diagnostic methods and can be addressed be some sort of medical intervention.
Many variants on the list increase a person’s risk of different kinds of cancer and could inform doctors and patients to start a more intensive tumor-screening...
Related Articles
By Pallab Gosh and Gwyndaf Hughes, BBC News | 06.26.2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.
The research has been taboo until now because of concerns it could lead to...
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...